Here are three things to know.
1. The Paris-based cosmetics company L’Oreal will pay $1.3 billion for Valeant’s three over-the-counter skin care brands: CerAve, AcneFree and Ambi. The three brands have combined annual sales of $168 million.
2. The Chinese conglomerate Sanpower Group will acquire Valeant’s cancer drug unit, Dendreon Pharmaceuticals, for $820 million. Valeant acquired Dendreon for $445 million in 2015.
3. The deals represent Valeant’s largest divestitures in almost three years and will help decrease the drugmaker’s $30 billion debt pile, according to Bloomberg.
More articles on supply chain:
Naloxone now available free-of-charge for at-risk youth in Oklahoma
St. Jude Medical releases cybersecurity updates for vulnerable heart devices
Egalet earns FDA approval for abuse-deterrent opioid painkiller
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
